



Title	Serum Krebs von den Lungen-6 levels in psoriatic patients under treatment with biologics
Author(s)	Iwata, Hiroaki; Haga, Naoya; Sugai, Tatsuro; Fujita, Yasuyuki
Citation	Journal of dermatology, 48(3), 376-379 https://doi.org/10.1111/1346-8138.15665
Issue Date	2021-03
Doc URL	http://hdl.handle.net/2115/84225
Rights	"This is the peer reviewed version of the following article: Iwata, H., Haga, N., Sugai, T. and Fujita, Y. (2021), Serum Krebs von den Lungen 6 levels in psoriatic patients under treatment with biologics. J. Dermatol., 48: 376-379, which has been published in final form at https://doi.org/10.1111/1346-8138.15665 . This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Use of Self-Archived Versions."
Type	article (author version)
File Information	J Dermatol_KL-6 in psoriasis with biologics.pdf



[Instructions for use](#)

1 Serum KL-6 levels in psoriasis patients under treatment with biologics

2

3 Hiroaki Iwata, Naoya Haga, Tatsuro Sugai, Yasuyuki Fujita

4

5 Running head: KL-6 in psoriasis with biologics

6

7 Department of Dermatology, Faculty of Medicine and Graduate School of Medicine Hokkaido

8 University

9

10 North 15 West 7, Kita-ku, Sapporo 060-8638, Japan

11 Tel: +81-11-706-7387

12 Fax: +81-11-706-7820

13

14 Correspondence: Hiroaki Iwata

15 Department of Dermatology, Faculty of Medicine and Graduate School of Medicine Hokkaido

16 University,

17 North 15 West 7, Kita-ku, Sapporo 060-8638, Japan

18 E-mail: hiroaki.iwata@med.hokudai.ac.jp

1 **Key words:** KL-6, psoriasis, biologics, tumor necrosis factor α , MUC1, methotrexate

2

3 Word count: 1,494 words (including abstract)

4 Figures: 2

5 Table: 1

6 References: 15

7

8 Financial disclosure: None to report

9 Publishable disclosure: The authors have no conflict of interest to declare.

10

1 **Abstract**

2 During biological treatments, attention should be paid to adverse reactions, particularly to infectious
3 diseases. Furthermore, drug-induced interstitial lung disease (ILD) is also known to be associated with
4 biological therapies. We retrospectively reviewed serum KL-6 levels in psoriasis patients who
5 underwent treatment with 7 different biologics. A total of 67 patients who received 80 biological
6 treatments were evaluated. The 31 anti-TNF α treatments consisted of 17 infliximab (IFX) and 14
7 adalimumab (ADA). The 23 anti-IL23 treatments consisted of 14 ustekinumab (UST) and 9
8 guselkumab (GUS). The 26 anti-IL17 treatments consisted of 9 secukinumab (SEC), 6 ixekizumab
9 (IXE), and 11 brodalumab (BRO). The IFX showed significantly increased mean serum KL-6
10 (170.9%), but none of the other treatments showed significant increases. 13 of the 17 (75.6%) patients
11 in the IFX and 17 of the 31 (54.8%) patients in the total anti-TNF α group demonstrated at least a 25%
12 increase in serum KL-6. Levels exceeding the cutoff (500 U/ml) were detected in 3 patients before
13 treatment and in 7 patients after treatment. This study showed that anti-IL17 and anti-IL23 treatments
14 have no significant impact of serum KL-6 level. In addition to the influence of IFX, a significantly
15 large number of patients in the IFX group have a history of MTX administration associated with
16 psoriatic arthritis, which may influence the KL-6 level. None of the patients with elevated serum
17 KL-6 showed pulmonary changes by CT scan and/or X-ray.

18

1 Introduction

2 Biologics are known to be highly effective against severe psoriasis vulgaris and psoriatic
3 arthritis. Regarding the pathomechanisms of psoriasis, several cytokines, including tumor
4 necrosis factor (TNF) α , interleukin (IL)-23, and IL-17, play critical roles, and biologics block
5 these cytokines or their receptors. Several adverse reactions caused by biological therapies have
6 been reported^{1,2}. Under anti-TNF α therapies for psoriasis, interstitial lung disease (ILD) was
7 reported as an adverse event^{3,4}. Krebs von den Lungen-6 (KL-6), which is a human mucin-1
8 (MUC1) protein, is a mucinous sialylated sugar chain on MUC1⁵. MUC1 is expressed by mucus
9 epithelial cells in various organs, such as the lungs, stomach, and intestines. MUC1 consists of
10 three domains: extracellular, transmembrane, and intracellular⁶. The extracellular domain of
11 MUC1 is highly glycosylated, and one sialylated sugar chain is recognized by anti-KL-6 mAb⁵.
12 Serum KL-6 levels are elevated not only with ILD, but also with several adenocarcinomas,
13 including colon cancer, breast cancer and pancreas cancer⁶. In ILD, KL-6 is produced by type II
14 pneumocytes⁷.

15 Several studies have investigated the influence of biologics on serum KL-6 levels⁸⁻¹¹.
16 We here retrospectively review KL-6 levels in psoriasis patients who received 7 different
17 biological treatments.

18

1 **Methods**

2 This study was approved by the Hokkaido University Certified Review Board and was
3 performed in accordance with the Declaration of Helsinki. We retrospectively reviewed patient
4 information from 2010 January to 2019 December, including psoriasis patients treated with
5 biologics. The study analyzed patients whose blood tests included KL-6 level at least twice during
6 their observation period. We took blood samples and chest X-rays regularly according to the
7 Japanese guidelines for biologic interventions for psoriasis¹². Serum KL-6 levels were measured
8 by chemiluminescent enzyme immunoassay (Sekisui Medical, Tokyo, Japan), and 500 U/ml was
9 considered the upper limit for normal. None of the patients had active adenocarcinomas, which
10 are known to elevate KL-6 levels.

11 To compare KL-6 levels before versus after biologics therapy, p-values were determined
12 using the Student's t-test.

13

14 **Results**

15 Serum KL-6 levels were found to be significantly elevated after anti-TNF α treatment

16 A total of 67 patients and 80 biological treatments (median age: 57 years; Male:Female
17 = 51:29) were evaluated, and the results are summarized in Table 1. The 31 anti-TNF α treatments
18 consisted of 17 patients for IFX and 14 patients for ADA. The 23 anti-IL23 treatments consisted

1 of 14 patients for UST and 9 patients for GUS. The 26 anti-IL17 treatments consisted of 9 patients
2 for SEC, 6 patients for IXE, and 11 patients for BRO. Psoriatic arthritis (PsA) patients were found
3 the most frequently in anti-TNF α group (58.1%), followed by the anti-IL23 group (43.5%) and
4 the anti-IL-17 group (38.5%). In the anti-TNF α group, 54.8% of the patients had a history of
5 methotrexate (MTX) administration. After the biologics treatments started, the IFX group showed
6 significantly elevated KL-6 (170.9%, $p=0.014$) and the ADA group also tended to show elevated
7 KL-6 (122.4%, $p=0.051$), but the ADA results were not statistically significant. No other
8 treatments showed significant elevation of KL-6. Regarding the targeting of cytokines, the anti-
9 TNF α treatments resulted in significantly increased KL-6 (146.6%, $p=0.002$). Next, we evaluated
10 the ratio of change in KL-6 after treatment of with biologics. 13 of 17 the patients (75.6%) who
11 were treated with IFX demonstrated at least a 25% increase in KL-6 level. In contrast, no other
12 treatments, including ADA, showed any high ratios of change. In the total anti-TNF α group, 17
13 of 31 the patients (54.8%) showed at least a 25% increase in KL-6 level. Serum KL-6 was above
14 the normal cutoff (500 U/ml) in 3 patients before treatment and in 7 patients after treatment. Four
15 patients—1 for IFX (1547 U/ml), 2 for GUS (988 U/ml), and 2 for SEC (519 U/ml, and 743
16 U/ml)—had KL-6 >500U/ml before treatment. In the anti-TNF α group, 4 IFX patients and 1 ADA
17 patient showed increased KL-6 after treatment. The changes in KL-6 for each patient who
18 underwent anti-TNF α treatment are shown in Figure 1.

1

2 Changes in serum KL-6 in 7 patients

3 The patients with KL-6 >500 U/ml are detailed in Figure 2. KL-6 increased slowly under
4 treatment with ADA (case 1), IFX (case 4) and SEC (case 7). Case 2 was treated for pneumocystis
5 pneumonia, and IFX was introduced after the pneumonia treatment had finished. KL-6 quickly
6 decreased to the normal range. Case 3 showed mild interstitial pulmonary changes by CT scan
7 before IFX treatment. After the IFX treatment started, KL-6 increased by several times, but a CT
8 scan showed no apparent interstitial changes. KL-6 was increased to 988 U/ml and 743 U/ml in
9 case 5 and case 6, after which we replaced the IFX with GUS and SEC, respectively. In case 5, a
10 CT scan showed no pulmonary changes at the highest KL-6. After the change to GUS, KL-6
11 quickly decreased to the normal range. In case 6, KL-6 decreased after the change to SEC. The
12 patient had pleurisy with SEC treatment (black arrow), and KL-6 was slightly elevated after the
13 pleurisy. Case 4 and case 5 had a history of MTX administration; the MTX was started 17 months
14 before the IFX in case 4, and 6 months after the IFX in case 5. ILD was not detected by CT scan
15 or chest X-ray in any of the patients who demonstrated elevated KL-6.

16

17 **Discussion**

18 We retrospectively reviewed the medical records of psoriasis patients treated with

1 biologics at our department. Consistent with previous reports⁸⁻¹¹, anti-TNF α agents were found
2 to significantly induce increases in KL-6. In our study, both UST and GUS were found to pose
3 less risk of this. In addition, it is a first evidence that our study demonstrated that IXE and BRO
4 have no impact on serum KL-6 level.

5 A previous study found that 55% of psoriasis patients undergoing anti-TNF α treatment
6 showed serum KL-6 elevated by 20% or more from the baseline¹¹. Furthermore, it was reported
7 that approximately 10-20% of rheumatoid arthritis (RA) patients receiving anti-TNF α agents
8 show increased serum KL-6^{1,13,14}. Our study found a statistically significant increase in serum
9 KL-6 during anti-TNF α treatment. 2 out of 7 patients were switched from IFX to other biologics,
10 after which serum KL-6 quickly decreased to the normal range (Figure 2, case 5 and case 6).
11 However, several patients demonstrated decreases in serum KL-6 under anti-TNF α treatment.
12 Decreases in serum KL-6 during anti-TNF α treatment have also been reported in rheumatoid
13 arthritis and psoriasis patients^{1,13}. The causal mechanism behind ILD from anti-TNF α agents
14 remains unclear. Several previous studies demonstrated the elevation of TNF α -converting
15 enzyme (TACE) in psoriasis patients¹⁵. TACE enhances soluble TNF α from membrane TNF α ;
16 however, TACE sheds the ectodomain of MUC1⁶. In addition to anti-TNF α agents, MTX is well
17 known as a risk factor for ILD. As expected, MTX administration was highly associated with PsA.
18 In this study, a significantly higher number of patients in the anti-TNF α group have a history of

1 MTX administration than those in the other treatment groups. The mean rate of change for KL-6
2 level in IFX with MTX is higher than that of IFX without MTX, but this difference is not
3 significant.

4 There are several limitations to this study. We did not consider the comorbidities. Some
5 comorbidities, especially inflammatory bowel disease and uveitis, strongly influence the selection
6 of biologics for psoriasis patients and also may be associated with ILD.

7 This study has shown the degree to which anti-TNF α agents, especially IFX, cause
8 serum KL-6 to increase. However, such increases with anti-TNF α therapies do not seem to be
9 directly associated with clinical ILD in most cases. In addition, several factors such as disease
10 type, MTX administration and comorbidities may influence serum KL-6 level. To resolve this
11 issue, basic research and prospective clinical research should be conducted.

12

1 **References**

- 2 1. Curtis JR, Sarsour K, Napalkov P, Costa LA, Schulman KL. Incidence and complications of interstitial
3 lung disease in users of tocilizumab, rituximab, abatacept and anti-tumor necrosis factor α agents, a
4 retrospective cohort study. *Arthritis Res Ther* 2015;**17**:319.
- 5 2. Caccaro R, Savarino E, D’Inca R, Sturniolo GC. Noninfectious interstitial lung disease during
6 infliximab therapy: Case report and literature review. *World J Gastroenterol* 2013;**19**:5377–80.
- 7 3. Phang KF, Teng GG, Teo LLS, Seet JE, Teoh CM, Teo FSW. A 67-Year-Old Man With Psoriatic
8 Arthritis and New-Onset Dyspnea. *Chest* 2018;**154**:e127–34.
- 9 4. Bale J, Chee P. Acute alveolitis following infliximab therapy for psoriasis. *Australas J Dermatol*
10 2013;**54**:61–3.
- 11 5. Kohno N, Akiyama M, Kyoizumi S, Hakoda M, Kobuke K, Yamakido M. Detection of soluble tumor-
12 associated antigens in sera and effusions using novel monoclonal antibodies, KL-3 and KL-6, against
13 lung adenocarcinoma. *Jpn J Clin Oncol* 1988;**18**:203–16.
- 14 6. Brayman M, Thathiah A, Carson DD. MUC1: a multifunctional cell surface component of reproductive
15 tissue epithelia. *Reprod Biol Endocrinol* 2004;**2**:4.
- 16 7. Inoue Y, Barker E, Daniloff E, Kohno N, Hiwada K, Newman LS. Pulmonary epithelial cell injury and
17 alveolar-capillary permeability in berylliosis. *Am J Respir Crit Care Med* 1997;**156**:109–15.
- 18 8. Kajihara I, Yamada-Kanazawa S, Maeda-Otsuka S, Jinnin M, Akaike K, Ihn H. Secukinumab-induced

- 1 interstitial pneumonia in a patient with psoriasis vulgaris. *Journal of Dermatology* 2017;**44**:e322–3.
- 2 9. Chijiwa C, Takeoka S, Kamata M, *et al.* Secukinumab decreases serum Krebs von den Lungen 6 (KL-
- 3 6) level in patients with psoriasis with elevated serum KL-6 level. *British Journal of Dermatology*
- 4 2018;**179**:1396–7.
- 5 10. Yanaba K, Umezawa Y, Sakakihara R, *et al.* Infliximab and adalimumab, unlike ustekinumab,
- 6 increase serum KL-6 levels in Japanese patients with psoriasis. *Journal of Dermatology* 2015;**42**:828–9.
- 7 11. Hayashi M, Yanaba K, Umezawa Y, Asahina A, Nakagawa H. Impact of anti-tumor necrosis factor- α
- 8 agents on serum levels of KL-6 and surfactant protein-D in patients with psoriasis. *J Dermatol*
- 9 2017;**44**:1063–6.
- 10 12. Ohtsuki M, Terui T, Ozawa A, *et al.* Japanese guidance for use of biologics for psoriasis (the 2013
- 11 version). *J Dermatol* 2013;**40**:683–95.
- 12 13. Harigai M, Takamura A, Atsumi T, *et al.* Elevation of KL-6 serum levels in clinical trials of tumor
- 13 necrosis factor inhibitors in patients with rheumatoid arthritis: a report from the Japan College of
- 14 Rheumatology Ad Hoc Committee for Safety of Biological DMARDs. *Mod Rheumatol* 2013;**23**:284–96.
- 15 14. Takahashi K, Nakamura H, Takenouchi K, *et al.* Serum KL-6 elevation and possible pulmonary
- 16 involvement in patients with rheumatoid arthritis treated with biological agents. *J Nippon Med Sch*
- 17 2014;**81**:364–71.
- 18 15. Kawaguchi M, Mitsuhashi Y, Kondo S. Overexpression of tumour necrosis factor- α -converting

1 enzyme in psoriasis. *Br J Dermatol* 2005;**152**:915–9.

2

3

4

1 **Figure legend**

2

3 Figure 1 Changes in serum KL-6 levels after anti-TNF α treatments

4 The dotted line indicates the normal limit.

5 * One patient was omitted from the graph but not from the table due to particularly high serum KL-6
6 before IFX treatment (1,547 U/ml before IFX treatment, and 324 U/ml after).

7

8 Figure 2 Changes in serum KL-6 level with time course in representative patients

9 Serial serum KL-6 levels are shown in the graph for patients with >500 U/ml. In case 5 and case 6, the
10 first biologic was replaced by a different one during the course (red line). Case 6 had pleurisy during
11 SEC treatment (black arrow). MTX was started 17 months before IFX in case 4, and 6 months after
12 IFX in case 5.

13

KL-6 in psoriasis with biologics


Treatment	N	PsA N(%)	Median age (range)	Gender M:F	MTX N (%)	Mean KL-6 (U/ml)		Mean rate of change (SD)	≥125% N (%)	After
						Before (SD)	After (SD)			≥500 U/ml N (%)
IFX	17	10 (58.8%)	50 (27-70)	12:5	11 (64.7%)	295.9 (333.4)*	391.8 (243.0)#	170.9% (93.7)	13(76.5%)	4 (23.5%)
ADA	14	8 (57.1%)	50 (29-80)	8:6	6 (35.3%)	205.9 (54.2)	253.7 (88.8)	122.4% (20.2)	4 (28.6%)	1 (7.1%)
UST	14	6 (42.9%)	64 (38-79)	8:6	2 (14.3%)	201.5 (40.5)	237.9 (86.1)	116.7% (24.7)	5 (35.7%)	
GUS	9	4 (44.4%)	59 (52-78)	6:3	3 (33.3%)	317.3 (256.4)*	260.9 (63.3)	102.3% (32.4)	2 (22.2%)	
SEC	9	3 (33.3%)	56 (41-74)	7:2	2 (22.2%)	287.4 (205.5)*	293.9 (181.2)	107.6% (22.8)	3 (33.3%)	1 (11.1%)
IXE	6	4 (66.7%)	66.5 (62-78)	2:4	0 (0%)	202.4 (45.7)	211.2 (87.3)	107.3% (29.8)	1 (16.7%)	
BRO	11	3 (27.3%)	47 (32-76)	8:3	1 (9.1%)	217.6 (61.7)	241.6 (56.6)	114.4% (20.7)	3 (27.2%)	
Total	80	38 (47.5%)	57 (27-80)	51:29	25 (31.3%)	246.5 (192.6)	280.8 (151.2)	125.5 (53.1)	31 (38.8%)	
TNF	31	18 (58.1%)	50 (27-80)	20:11	17 (54.8%)	250.9 (250.3)	322.7 (199.5)#	146.6% (73.9)	17 (54.8%)	5 (16.1%)
IL23	23	10 (43.5%)	59 (38-79)	14:9	5 (21.7%)	259.4 (168.0)	249.4 (77.3)	109.5% (28.2)	7 (30.4%)	
IL17	26	10 (38.5%)	60.5 (32-78)	17:9	3 (11.5%)	235.8 (130.5)	248.9 (120.0)	109.7% (23.0)	7 (26.9%)	1 (3.8%)

1 Table 1 Overall results of serum KL-6 levels in psoriasis patients under treatment with biologics

2

3 * Four patients, one IFX, one GUS and two SEC, showed >500 U/ml of serum KL-6 level before

4 starting treatments. # p<0.05



* One patient deleted due to extremely high score before IFX treatment.

